Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.2 CHF | +0.75% | 0.00% | +13.88% |
05-03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
04-09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.88% | 532M | |
+21.15% | 47.9B | |
+46.56% | 41.42B | |
-2.36% | 40.7B | |
-6.20% | 28.92B | |
+10.68% | 25.55B | |
-21.68% | 19.27B | |
-1.94% | 12.15B | |
+31.05% | 12.14B | |
-0.74% | 11.99B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Basilea Seeks US FDA's Investigational New Drug Approval For Cancer Therapy